Raj. CHO -2020: What is the duration of treatment for Multi-Drug Resistant Tuberculosis (MDR-TB)?

Raj. CHO -2020

Community Health Nursing

Easy

Appeared in: Raj. CHO -2020

Explanation

Multi-Drug Resistant Tuberculosis (MDR-TB) is defined by resistance to at least the two most effective first-line drugs: isoniazid (H) and rifampin (R).
The loss of these primary drugs necessitates a longer treatment course using a combination of second-line agents, which are generally less potent and may have more side effects.
The conventional extended regimen for MDR-TB, as recommended by global health authorities, requires a treatment duration of at least 18 to 24 months to ensure a cure and prevent relapse.
Recent guidelines also include shorter all-oral regimens (e.g., 6-9 months), but the 18-20 month regimen remains a crucial option, especially for complex cases or when shorter regimens are not suitable.

Option A: This is the standard treatment duration for drug-susceptible tuberculosis, which responds well to first-line drugs.
Option B: While newer, shorter regimens for eligible MDR-TB patients can be around 9-12 months, this is not the duration of the conventional, longer regimen which is still a standard of care.
Option D: This duration is excessively long for a standard MDR-TB case and is typically reserved for more severe forms of drug resistance or treatment complications.

Visual 1: Table - A comparative table showing the drug regimens and treatment durations for Drug-Susceptible TB, MDR-TB, and XDR-TB. This helps learners visually contrast the increasing complexity and length of treatment as drug resistance increases.

Clinical Relevance

Nursing practice connection: Knowing Treatment duration for Multi-Drug Resistant Tuberculosis (MDR-TB) helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
Nurses are central to managing MDR-TB patients, primarily through administering Directly Observed Therapy (DOT). Ensuring strict adherence to the long and arduous 18-24 month regimen is critical to prevent treatment failure and the emergence of even more dangerous Extensively Drug-Resistant TB (XDR-TB).
Patient education is a key nursing responsibility. Nurses must explain the importance of completing the full course of treatment, manage expectations about the long duration, and provide support for managing side effects of second-line drugs.
What if? If a patient with MDR-TB is found to also have resistance to a fluoroquinolone, they may be classified as having pre-XDR-TB. This would make them ineligible for some shorter regimens and would necessitate a longer, individualized regimen, often exceeding 20 months, designed in consultation with a specialist.

How to Approach the Question

First, identify the specific disease in the question: 'Multi-Drug Resistant Tuberculosis (MDR-TB)'.
Recall the definition of MDR-TB, which is resistance to the two most powerful first-line drugs (isoniazid and rifampin).
Logically deduce that if the best drugs don't work, the treatment must be longer and use different, second-line drugs.
Eliminate the shortest option (6-8 months), as this is the well-known duration for standard, drug-susceptible TB.
Compare the remaining longer durations. Recall that the conventional, standard treatment for MDR-TB is a prolonged course, making 18-24 months the most plausible and widely cited duration.

Concept Tested & Keywords

Concept Tested: Treatment duration for Multi-Drug Resistant Tuberculosis (MDR-TB)
Stem keywords: duration of treatment, Multi-Drug Resistant Tuberculosis, MDR-TB
Lead-in keywords: What is

QHfC2__oSghwIRrKDAqceo

E6 Comprehensive Textbook of Community Health Nursing for BSc Nursing Students Part 2 — Subpart B (pp 276-535 of 550) p. 276-550